Success stories

Nanoform Expands Commercial Presence in Asia with A&LS Pharma in South Korea

Discover more

Expanding Opportunities for Inhaled Drug Delivery

Discover more

Nanoform Secures €5 Million R&D Loan from Business Finland to Advance Clinical Development of Nanoapalutamide

Discover more

Nanoform starts Pivotal Human Bioequivalence Studies of Nanoenzalutamide

Discover more

Development of Nanoformed Trastuzumab for Subcutaneous Injection to Be Presented at DDF Summit in Berlin

Discover more

Positive nanoform biologics respiratory data to be presented at drug delivery and formulation summit

Discover more

Inside information made public: Nanoform partners with two specialist healthcare investors to develop and commercialise Nanoencorafenib

Discover more

Nanoform High Dose Subcutaneous Delivery of Biologics

Discover more

Nanoform and Celanese Expand Collaboration into Long-Acting Biologics Delivery Through Small Implants

Discover more

Nanoform successfully completes new share issue raising EUR 15.4 million to invest in commercialization of nanoparticle enabled formulations for next generation medicines

Discover more

Nanoform Enters Exclusive Partnership with CBC to Bring Best-in-Class Nanomedicine Technology to Japan

Discover more

Nanoform and PlusVitech partner to repurpose aprepitant as a treatment for lung cancer

Discover more

Apalutamide Study Again Demonstrates the Advantages of Nanoforming Over Traditional Cancer Treatment Formulations

Discover more

Inside information made public: Nanoform Wins R&D Grant of EUR 4.3M for Research Into Nanoparticle Enabled Formulations for Next Generation Medicines

Discover more

Inside information made public: Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide

Discover more

Nanoform Q3 2023: Nanoformed blockbuster drug enters clinic and another nanoformed drug received FDA orphan designation

Discover more

Nanoform and Pharmanovia to breathe new life into iconic medicines

Discover more

Nanoform’s collaboration with TargTex

Discover more

Nanoform launches “STARMAP® Online” placing AI-power at the fingertips of medicine developers

Discover more

Nanoform successfully completes new share issue raising EUR 25 million to prepare for GMP manufacturing in the USA

Discover more

Nanoform triples its GMP capacity and adds high potent handling (OEL <30 ng/m3) capabilities to its Helsinki facility to meet increasing demand.

Discover more

Nanoform wins Star of Innovation award at the European Small and Mid-Cap Awards 2021

Discover more

Nanoform receives funding to solve challenges for global health

Discover more

Nanoform technology delivers successful results for Herantis CDNF drug candidate

Discover more

Nanoform and Boehringer Ingelheim execute master services agreement

Discover more

Nanoform’s final clinical results confirm value proposition to the pharma industry

Discover more

Nanoform awarded GMP certification

Discover more

Nanoform wins the CPhI Excellence in Pharma Award for Formulation

Discover more

Our nanoforming technologies, formulation and analytical services span the full range of drug development from small-molecule to large-molecule therapeutics

Discover more Contact us

Nanoform Expands Commercial Presence in Asia with A&LS Pharma in South Korea

Expanding Opportunities for Inhaled Drug Delivery

Nanoform Secures €5 Million R&D Loan from Business Finland to Advance Clinical Development of Nanoapalutamide

Nanoform starts Pivotal Human Bioequivalence Studies of Nanoenzalutamide

Development of Nanoformed Trastuzumab for Subcutaneous Injection to Be Presented at DDF Summit in Berlin

Positive nanoform biologics respiratory data to be presented at drug delivery and formulation summit

Inside information made public: Nanoform partners with two specialist healthcare investors to develop and commercialise Nanoencorafenib

Nanoform High Dose Subcutaneous Delivery of Biologics

Nanoform and Celanese Expand Collaboration into Long-Acting Biologics Delivery Through Small Implants

Nanoform successfully completes new share issue raising EUR 15.4 million to invest in commercialization of nanoparticle enabled formulations for next generation medicines

Nanoform Enters Exclusive Partnership with CBC to Bring Best-in-Class Nanomedicine Technology to Japan

Nanoform and PlusVitech partner to repurpose aprepitant as a treatment for lung cancer

Apalutamide Study Again Demonstrates the Advantages of Nanoforming Over Traditional Cancer Treatment Formulations

Inside information made public: Nanoform Wins R&D Grant of EUR 4.3M for Research Into Nanoparticle Enabled Formulations for Next Generation Medicines

Inside information made public: Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide

Nanoform Q3 2023: Nanoformed blockbuster drug enters clinic and another nanoformed drug received FDA orphan designation

Nanoform and Pharmanovia to breathe new life into iconic medicines

Nanoform’s collaboration with TargTex

Nanoform launches “STARMAP® Online” placing AI-power at the fingertips of medicine developers

Nanoform successfully completes new share issue raising EUR 25 million to prepare for GMP manufacturing in the USA

Nanoform triples its GMP capacity and adds high potent handling (OEL <30 ng/m3) capabilities to its Helsinki facility to meet increasing demand.

Nanoform wins Star of Innovation award at the European Small and Mid-Cap Awards 2021

Nanoform receives funding to solve challenges for global health

Nanoform technology delivers successful results for Herantis CDNF drug candidate

Nanoform and Boehringer Ingelheim execute master services agreement

Nanoform’s final clinical results confirm value proposition to the pharma industry

Nanoform awarded GMP certification

Nanoform wins the CPhI Excellence in Pharma Award for Formulation

Share